APCCC 2022 VL

PSMA PET Imaging Hot Topics - Neal Shore & Jason Efstathiou

Details
Neal Shore and Jason Efstathiou join Alicia Morgans at APCCC 2022 to discuss the current landscape in PSMA PET imaging. Drs Shore and Efstathiou share their thoughts on the agents they are using and the impacts of these new developments in imaging on staging and prognostication. Biographies: Jason Efstathiou, MD, Radiation Oncologist Professor of Radiation Oncology, Harvard Medical School, Vice-Ch...

A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore

Details
Neal Shore and Alicia Morgans discuss the changing landscape in metastatic castration-resistant prostate cancer, where we've had the recent approval of Lutetium (177 Lu-PSMA-617), and they focus on sequencing these therapies, especially in the setting of triplet therapies coming in the metastatic hormone-sensitive disease setting. For most patients with metastatic castration-sensitive prostate can...

Lutetium-617 - Treatment Sequencing Considerations for Metastatic Castration-Resistant Prostate Cancer - Neal Shore

Details
Neal Shore joins Alicia Morgans during APCCC 2022 to discuss sequencing strategies to implement lutetium-617 for patients with metastatic castration-resistant prostate cancer (mCRPC). Drs. Shore and Morgans consider the many treatment options now available as Dr. Shore emphasizes that monotherapy should no longer be an option. Finally, important concerns about bone health and its impact on treatme...

APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu

Details
Evan Yu discusses the changing landscape of metastatic hormone-sensitive prostate cancer treatment with Alicia Morgans. Dr. Yu provides an overview of the many important questions and concerns clinicians must address in sequencing treatment for mCRPC patients in light of novel hormone therapy agents and the opportunity for triplet therapy. Biographies: Evan Yu, MD , Professor, Department of Medici...

Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans

Details
Alicia Morgans and Matthew Smith join Charles Ryan to discuss cancer survivorship. Drs Morgans and Smith explain the holistic role that a cancer survivorship program plays in the health and well-being of prostate cancer patients, including bone health, mental health, monitoring cardiovascular risk, and more. Biographies: Matthew R. Smith, MD, Ph.D., Professor of Medicine, Harvard Medical School, A...

Immune Checkpoint B7-H3 - APCCC 2022 - Emmanuel Antonarakis

Details
Emmanuel Antonarakis joins Alicia Morgans to discuss the immune checkpoint B7-H3 and its implications for prostate cancer treatment. Dr. Antonarakis provides an overview of clinical trials that tested B7-H3 and the encouraging findings of those trials. He also details some of the toxicities noted during the trials and plans for future studies given the measurable disease responses and PSA response...

Optimal Sequencing - Should It Include Radium Given Lutetium? - Joe O'Sullivan

Details
Joe O’Sullivan joins Alicia Morgans in a conversation about metastatic castration-resistant prostate cancer and the recent approval of lutetium-PSMA-617. As a radiation oncologist, Dr. O’Sullivan shares his views on effective sequencing of radium-223 and lutetium-177 for patients, especially given previous lines of treatment. Biographies: Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR, Professor of R...

Genomic and Clinical Markers in nmCRPC APCCC 2022 Presentation - Joaquin Mateo

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Joaquin Mateo presents genomic and clinical markers in non-metastatic castrate-resistant prostate cancer (nmCRPC). Biographies: Joaquin Mateo, MD, PhD, Medical Oncologist, Attending Physician, and Principal Investigator, Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelo...

How To Interpret and Confirm Lesions Positive on PSMA PET but With No Correlation on CT? APCCC 2022 Presentation - Stefano Fanti

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Stefano Fanti presents on the treatment of patients with oligometastatic and oligoprogressive prostate cancer, focusing on how to interpret and confirm lesions detected on PSMA-PET that don’t have correlates on conventional imaging. Biographies: Stefano Fanti, MD, Professor, Department of Experimental, Diagnostic and Specialty Medi...

Does “Oligoprogressive” Prostate Cancer Exist as a Distinct Clinically Meaningful Entity and if Yes, How To Treat It? APCCC 2022 Presentation - Robert Jones

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Robert Jones presents on the treatment of patients with oligometastatic and oligoprogressive prostate cancer, focusing on whether “oligoprogressive” prostate cancer exists as a distinct clinical entity. Biographies: Robert Jones, MD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK Related Content: APCCC...
email news signup